Evidence map›Paper›PMID 39195320›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Equitable Access to Genomic Molecular Testing for Australian Cancer Patients: Insights from the Victorian Precision Oncology Summit.

Genevieve Dall, Karen Harris, Nonie Chan, Stephen J Luen, Sophia Frentzas, Daphne Day, Michelle Barrett, Anna Kilgour, Mark Buzza

Abstract readConference Proceedings
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Genevieve DallVictorian Comprehensive Cancer Centre Alliance (VCCC Alliance), Victorian Comprehensive Cancer Centre, Parkville, VIC 3052, Australia.
Karen HarrisMonash Partners Comprehensive Cancer Consortium (MPCCC), Monash University, Clayton, VIC 3800, Australia.
Nonie ChanVictorian Comprehensive Cancer Centre Alliance (VCCC Alliance), Victorian Comprehensive Cancer Centre, Parkville, VIC 3052, Australia.
Stephen J LuenDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, VIC 3052, Australia.
Sophia FrentzasDepartment of Medical Oncology, Monash Health and Monash University, Clayton, VIC 3168, Australia.
Daphne DayDepartment of Medical Oncology, Monash Health and Monash University, Clayton, VIC 3168, Australia.ORCID 0000-0001-8262-2441
Michelle BarrettVictorian Comprehensive Cancer Centre Alliance (VCCC Alliance), Victorian Comprehensive Cancer Centre, Parkville, VIC 3052, Australia.
Anna KilgourMonash Partners Comprehensive Cancer Consortium (MPCCC), Monash University, Clayton, VIC 3800, Australia.
Mark BuzzaVictorian Comprehensive Cancer Centre Alliance (VCCC Alliance), Victorian Comprehensive Cancer Centre, Parkville, VIC 3052, Australia.ORCID 0000-0003-4343-0812

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Victorian Precision Oncology Summit, convened in 2023, was a joint initiative between the Victorian Comprehensive Cancer Centre Alliance (VCCC Alliance) and the Monash Partners Comprehensive Cancer Consortium (MPCCC) and was proposed to guide a coordinated state-wide conversation about how the oncology sector can overcome some of the current obstacles in achieving equity of access to clinical cancer genomics for Victorian patients. Themes that emerged from discussion groups at the Summit include standardisation, centralisation, funding, education and communication and insights across those themes are outlined in this manuscript. The event served as a large consultation piece for the development of a broader precision oncology roadmap, which explores equitable access to molecular testing for Victorian patients, currently in development by the VCCC Alliance and MPCCC in collaboration with other key Victorian and national stakeholders. While this symposium was a Victorian initiative, it is felt that the insights garnered from this consultation piece will be of interest to consumer groups, clinicians, researchers, educators, policy makers and other key stakeholders in other states of Australia as well as in other countries implementing comprehensive genomic profiling within complex health systems.

Indexed as

GenomicsNeoplasmsPrecision MedicineAustraliaGenetic TestingHealth Services AccessibilityHumansMedical Oncologycancercomprehensive genomic profilingequitable accessgenomic testingprecision oncology

Identifiers

PMID39195320
PMCPMC11352575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.